Aytu BioPharma holder reports 4.99% stock stake

Aytu BioPharma, Inc. has a significant shareholder, Laurence W. Lytton, and the Lytton-Kambara Foundation jointly reporting beneficial ownership of Aytu common stock.

Rhea-AI Filing Summary

Aytu BioPharma, Inc. has a significant shareholder, Laurence W. Lytton, and the Lytton-Kambara Foundation jointly reporting beneficial ownership of Aytu common stock. Each reports 545,946 shares beneficially owned, representing 4.99% of the common stock, based on 10,733,208 shares outstanding as of April 30, 2026. All voting and dispositive powers are reported as shared, with no sole power held by either reporting person. The holdings include existing common shares and warrants to purchase additional shares, all subject to a 4.99% beneficial ownership limitation. The parties also provide a joint filing agreement covering their Schedule 13D or 13G submissions.

Key Figures

Beneficial ownership per reporting person: 545,946 shares Ownership percentage per reporting person: 4.99% Shares outstanding: 10,733,208 shares +1 more

4 metrics

Beneficial ownership per reporting person 545,946 shares Shares of Aytu BioPharma common stock beneficially owned by each of Laurence W. Lytton and the Lytton-Kambara Foundation

Ownership percentage per reporting person 4.99% Percent of Aytu BioPharma common stock class held by each reporting person

Shares outstanding 10,733,208 shares Aytu BioPharma common shares outstanding as of April 30, 2026, used for ownership calculations

Common shares in one holder’s position 338,344 shares Common stock portion of one reporting person’s position, with additional warrants subject to a 4.99% cap

Key Terms

beneficial ownership limitation, shared voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficial ownership limitation financial

"warrants to purchase shares of Common Stock, subject to a 4.99% beneficial ownership limitation"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

shared voting power financial

"Shared Voting Power 545,946.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 545,946.00"

Schedule 13G regulatory

"AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Amount beneficially owned: Lytton: 545,946 Foundation: 545,946"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in AYTU does Laurence W. Lytton report in this Schedule 13G/A?

Laurence W. Lytton reports 545,946 shares of Aytu BioPharma common stock as beneficially owned, representing 4.99% of the class, with all voting and dispositive power shared and none held solely.

How much of AYTU does the Lytton-Kambara Foundation beneficially own?

The Lytton-Kambara Foundation reports beneficial ownership of 545,946 Aytu BioPharma shares, equal to 4.99% of the outstanding common stock, with shared voting and dispositive power over all of these reported shares.

What is the beneficial ownership limitation disclosed for AYTU warrants in this filing?

The filing states that the reported Aytu holdings include common stock and warrants, all subject to a 4.99% beneficial ownership limitation, which effectively caps the reportable ownership percentage for the holder and the foundation.

What share count is used to calculate the 4.99% AYTU ownership reported?

The 4.99% ownership figure is calculated based on 10,733,208 Aytu BioPharma common shares outstanding as of April 30, 2026, as referenced from the issuer’s Form 10-Q for the quarter ended March 31, 2026.

Do Laurence W. Lytton and the Lytton-Kambara Foundation have sole or shared voting power over AYTU shares?

Both Laurence W. Lytton and the Lytton-Kambara Foundation report 0 sole voting and dispositive power and 545,946 shares of shared voting and shared dispositive power in Aytu BioPharma common stock.

What agreement is referenced between Laurence W. Lytton and the Lytton-Kambara Foundation regarding AYTU?

The filing includes Exhibit 99.1, an agreement regarding the joint filing of statements on Schedule 13D or 13G by Laurence W. Lytton and the Lytton-Kambara Foundation for their Aytu BioPharma holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 12:09 PM Accepted by SEC EDGAR 08/14/2026 - 12:08 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

AYTU BIOPHARMA, INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

054754858

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 054754858

1

Names of Reporting Persons

LYTTON LAURENCE W

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 545,946.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 545,946.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

545,946.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares of the Common Stock reported herein consist of 338,344 shares of Common Stock and warrants to purchase 731,666 shares of Common Stock, subject to a 4.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 10,733,208 shares of Common Stock outstanding as of April 30, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.

SCHEDULE 13G

CUSIP Number(s): 054754858

1

Names of Reporting Persons

LYTTON-KAMBARA FOUNDATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 545,946.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 545,946.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

545,946.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares of the Common Stock reported herein consist of 338,344 shares of Common Stock and warrants to purchase 398,310 shares of Common Stock, subject to a 4.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 10,733,208 shares of Common Stock outstanding as of April 30, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AYTU BIOPHARMA, INC
(b)	Address of issuer's principal executive offices: 7900 E. UNION AVENUE, SUITE 920, DENVER, CO, 80237
Item 2.
(a)	Name of person filing: Laurence W. Lytton and Lytton-Kambara Foundation ("Foundation")
(b)	Address or principal business office or, if none, residence: 467 Central Park West New York, NY 10025
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 054754858
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Lytton: 545,946 Foundation: 545,946
(b)	Percent of class: Lytton: 4.99% Foundation: 4.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Lytton: 0 Foundation: 0
	(ii) Shared power to vote or to direct the vote: Lytton: 545,946 Foundation: 545,946
	(iii) Sole power to dispose or to direct the disposition of: Lytton: 0 Foundation: 0
	(iv) Shared power to dispose or to direct the disposition of: Lytton: 545,946 Foundation: 545,946
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LYTTON LAURENCE W

Signature:	/s/ Laurence W. Lytton
Name/Title:	Reporting Person
Date:	08/13/2026

LYTTON-KAMBARA FOUNDATION

Signature:	/s/ Laurence W. Lytton
Name/Title:	President
Date:	08/13/2026

Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G